DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: OCREVUS (ocrelizumab)
       *****************************************************
       #Post#: 2712--------------------------------------------------
       Ocrelizumab and liver injury research information (PubMed)
   DIR By: agate
       Date: November 4, 2019, 6:43 pm
       ---------------------------------------------------------
       The Overview section of the report on Ocrevus that is part of a
       larger report entitled  LiverTox: Clinical and Research
       Information on Drug-Induced Liver Injury, issued by the National
       Institute of Diabetes and Digestive and Kidney Diseases. This
       section was last updated in July 2018.
  HTML https://www.ncbi.nlm.nih.gov/books/NBK548145/#Ocrelizumab.OVERVIEW
       The "likelihood score" for Ocrevus is E*, which is defined as:
       --- Quote ---
       > Category E*. The drug is suspected to be capable of causing
       liver injury or idiosyncratic acute liver injury but there have
       been no convincing cases in the medical literature. In some
       situations cases of acute liver injury have been reported to
       regulatory agencies or mentioned in large clinical studies of
       the drug, but the specifics and details supportive of causality
       assessment are not available. The agent is unproven, but
       suspected to cause liver injury.
       --- End Quote ---
       *****************************************************
       Page 1 of 1